# Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

> **NCT07201675** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 59 (estimated)

## Conditions studied

- Muscle Invasive Bladder Cancer (MIBC)

## Interventions

- **DRUG:** RC48-ADC combined with toripalimab for bladder-sparing therapy

## Key facts

- **NCT ID:** NCT07201675
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07201675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07201675, "Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07201675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*